BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32324779)

  • 1. Associations among smoking, MGMT hypermethylation, TP53-mutations, and relapse in head and neck squamous cell carcinoma.
    Matsuda S; Mafune A; Kohda N; Hama T; Urashima M
    PLoS One; 2020; 15(4):e0231932. PubMed ID: 32324779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
    J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
    Mafune A; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Imai S; Nakashima A; Yokoo T; Wada K; Kojima H; Urashima M
    BMC Cancer; 2015 Mar; 15():205. PubMed ID: 25886176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.
    Nagy E; Gajjar KB; Patel II; Taylor S; Martin-Hirsch PL; Stringfellow HF; Martin FL; Phillips DH
    Br J Cancer; 2014 Jun; 110(12):2874-80. PubMed ID: 24853176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India.
    Das M; Sharma SK; Sekhon GS; Saikia BJ; Mahanta J; Phukan RK
    Asian Pac J Cancer Prev; 2014; 15(22):9955-60. PubMed ID: 25520135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
    Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
    Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
    Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.
    Alonso S; Dai Y; Yamashita K; Horiuchi S; Dai T; Matsunaga A; Sánchez-Muñoz R; Bilbao-Sieyro C; Díaz-Chico JC; Chernov AV; Strongin AY; Perucho M
    Oncotarget; 2015 Feb; 6(5):3420-31. PubMed ID: 25638164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
    Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
    Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
    Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
    Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant gene promoter methylation of E-cadherin, p16
    Burassakarn A; Pientong C; Sunthamala N; Chuerduangphui J; Vatanasapt P; Patarapadungkit N; Kongyingyoes B; Ekalaksananan T
    Med Oncol; 2017 Jul; 34(7):128. PubMed ID: 28573642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence.
    Jahed M; Ebadi N; Mivehchi M; Majidizadeh T; Shahshanipour M; Asgari M; Ghadakzadeh S; Hosseini SA
    Cancer Biomark; 2016 Mar; 16(4):627-32. PubMed ID: 27002765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.